進行性腎細胞がん治療の世界市場：現状分析と予測（2022年～2028年）

世界の進行性腎細胞がん治療の市場規模は、予測期間中に約5％のCAGRで成長すると予測されています。標的治療薬の迅速な承認と従来治療薬と比較した高い有効性は、市場の成長を後押ししています。また、高齢者人口の増加、腎臓がんの有病率の上昇、医療支出の増加、製薬大手による投資の急増も、市場の成長を促進しています。

当レポートでは、世界の進行性腎細胞がん治療市場について調査しており、市場の洞察、市場動向、競合シナリオ、企業概要など、包括的な情報を提供しています。

目次

第1章 市場イントロダクション

• 市場の定義
• 主な目標
• ステークホルダー
• 制限

第2章 調査手法または仮定

• 進行性腎細胞がん治療市場の調査プロセス
• 進行性腎細胞がん治療市場の調査手法
• 回答者プロファイル

第3章 市場要約

第4章 エグゼクティブサマリー

第5章 進行性腎細胞がん治療市場に対するCOVID-19の影響

第6章 進行性腎細胞がん治療市場の収益（10億米ドル）（2020年～2028年）

第7章 市場の洞察：治療別

• 化学療法
• 生物製剤
• その他

第8章 市場の洞察：投与経路別

• 経口
• 非経口
• その他

第9章 市場の洞察：最終用途別

• 病院薬局
• 小売薬局
• オンライン薬局

第10章 市場の洞察：地域別

• 北米
  • 米国
  • カナダ
  • その他の北米
• 欧州
  • ドイツ
  • 英国
  • フランス
  • イタリア
  • スペイン
  • その他の欧州
• アジア太平洋
  • 中国
  • 日本
  • インド
  • その他のアジア太平洋地域
• 世界のその他の地域

第11章 進行性腎細胞がん治療の市場力学

• 市場促進要因
• 市場の課題
• 影響分析

第12章 進行性腎細胞がん治療の市場機会

第13章 進行性腎細胞がん治療の市場動向

第14章 需要側と供給側の分析

• 需要側分析
• 供給側分析

第15章 バリューチェーン分析

第16章 競合シナリオ

• 競合情勢
  • ポーターのファイブフォース分析

第17章 企業概要

• Bristol-Myers Squibb Company
• Novartis AG
• Pfizer Inc.
• Genentech, Inc
• GSK plc.
• Bayer AG
• Eisai Co., Ltd
• Exelixis, Inc.
• Merck KGaA
• NiKang Therapeutics, Inc.

第18章 免責事項

Renal cell carcinoma (RCC) represents about 0%-95% of kidney cancers. And, approximately, 30% of RCC cases are diagnosed at the advanced or metastatic stage. The mainstay treatment of advanced renal cell carcinoma include tyrosine kinase inhibitors, vascular endothelial growth factor inhibitors, chemotherapy, and other. However, with the increase in the understanding of cancer biology, researchers have developed novel targeted therapies such as monoclonal antibodies, immune checkpoint inhibitors, immune modulators, and others. For instance, in August 2021, U.S. FDA granted approval to the combination of lenvatinib (Lenvima) plus pembrolizumab (Keytruda) for first-line treatment of adult patients with advanced renal cell carcinoma. Thus, rapid approval of targeted therapies and their high efficacy in comparison to conventional therapies is driving the growth of the market.

The Advanced Renal Cell Carcinoma Treatment Market is expected to grow at a steady rate of around 5% owing to technological advancements and an increase in investment by pharmaceutical giants. The key players are rapidly launching novel products, which are also having a positive impact on market growth. For instance, in November 2021, NiKang Therapeutics Inc. entered into clinical trial collaboration with Pfizer Inc. The collaboration aims to evaluate NKT2152, a small molecule that inhibits hypoxia inducible factor 2α (HIF2α), in combination with palbociclib, a CDK4/6 inhibitor, and sasanlimab, a subcutaneously administered PD-1 inhibitor for the treatment of advanced clear cell renal cell carcinoma (ccRCC).

Based on treatment, the market is segmented into chemotherapy, biologics, and others. The biologics segment is expected to grow with a high CAGR during the forecast period which is attributed to its targeted nature, high cost, and high efficiency. Moreover, key players are launching products in the market which is also expected to have a positive impact on the growth of the market. For instance, in January 2021, U.S. FDA approved the combination of nivolumab (Opdivo) and cabozantinib (Cabometyx) as first-line treatment for patients with advanced renal cell carcinoma. The approval was on the basis of CHECKMATE-9ER trial, which demonstrated significant improvement in progression-free survival and overall survival rates.

On the basis of the route of administration, the market is categorized into oral, parenteral, and other. The oral route held a significant share of the market in 2020. It is the most common and acceptable route of administration as it is cheap, simple, and safest. Moreover, it is highly economical as does not involve the patient in extra cost. Thus, these factors are driving segmental growth.

On the basis of end-use, the market is segmented into hospital pharmacy, retail pharmacy, and online pharmacy. The hospital pharmacy held a significant share in the market in 2020. The rising prescription of medications at hospitals due to more frequent diagnoses at these institutions is a major factor driving the segment growth. Moreover, the increasing preference of patients to avail treatment in hospitals and the easy availability of medication in hospital pharmacies. Also, the tendency of consumers to visit hospital pharmacies for safe and authorized drugs is also driving the growth of this segment.

For a better understanding of the market adoption of the advanced renal cell carcinoma treatment, the market is analyzed based on its worldwide presence in the countries such as North America (U.S., Canada, Rest of North America), Europe (Germany, U.K., France, Spain, Italy, Rest of Europe), Asia-Pacific (China, Japan, India, Rest of Asia-Pacific), Rest of World. APAC is anticipated to grow at a substantial CAGR during the forecast period. Several factors, such as the rise in the geriatric population, the rise in the prevalence of kidney cancer, rising healthcare expenditures, and a surge in investments by pharmaceutical giants are driving the regional growth. For instance, in October 2022, Hutchmed initiated a Phase II/III trial of fruquintinib in combination with sintilimab as second-line treatment for locally advanced or metastatic renal cell carcinoma in China. The first patient in China received the first dose on October 27, 2022. Moreover, in March 2020, Japanese Ministry of Health, Labor and Welfare granted approval to cabometyx (cabozantinib) in Japan, for the treatment for patients with curatively unresectable or metastatic renal cell carcinoma.

Some of the major players operating in the market include: Bristol-Myers Squibb Company; Novartis AG; Pfizer Inc.; Genentech, Inc; GSK plc.; Bayer AG; Eisai Co., Ltd; Exelixis, Inc.; Merck KGaA; NiKang Therapeutics, Inc.

TABLE OF CONTENTS

1 MARKET INTRODUCTION

• 1.1. Market Definitions
• 1.2. Main Objective
• 1.3. Stakeholders
• 1.4. Limitation

2 RESEARCH METHODOLOGY OR ASSUMPTION

• 2.1. Research Process of the Advanced Renal Cell Carcinoma Treatment Market
• 2.2. Research Methodology of the Advanced Renal Cell Carcinoma Treatment Market
• 2.3. Respondent Profile

3 MARKET SYNOPSIS

4 EXECUTIVE SUMMARY

5 IMPACT OF COVID-19 ON THE ADVANCED RENAL CELL CARCINOMA TREATMENT MARKET

6 ADVANCED RENAL CELL CARCINOMA TREATMENT MARKET REVENUE (USD BN), 2020-2028F

7 MARKET INSIGHTS BY TREATMENT

• 7.1. Chemotherapy
• 7.2. Biologics
• 7.3. Others

8 MARKET INSIGHTS BY ROUTE OF ADMINISTRATION

• 8.1. Oral
• 8.2. Parenteral
• 8.3. Other

9 MARKET INSIGHTS BY END-USE

• 9.1. Hospital Pharmacy
• 9.2. Retail Pharmacy
• 9.3. Online Pharmacy

10 MARKET INSIGHTS BY REGION

• 10.1. North America
  • 10.1.1. U.S.
  • 10.1.2. Canada
  • 10.1.3. Rest of North America
• 10.2. Europe
  • 10.2.1. Germany
  • 10.2.2. U.K.
  • 10.2.3. France
  • 10.2.4. Italy
  • 10.2.5. Spain
  • 10.2.6. Rest of Europe
• 10.3. Asia-Pacific
  • 10.3.1. China
  • 10.3.2. Japan
  • 10.3.3. India
  • 10.3.4. Rest of Asia-Pacific
• 10.4. Rest of World

11 ADVANCED RENAL CELL CARCINOMA TREATMENT MARKET DYNAMICS

• 11.1. Market Drivers
• 11.2. Market Challenges
• 11.3. Impact Analysis

12 ADVANCED RENAL CELL CARCINOMA TREATMENT MARKET OPPORTUNITIES

13 ADVANCED RENAL CELL CARCINOMA TREATMENT MARKET TRENDS

14 DEMAND AND SUPPLY-SIDE ANALYSIS

• 14.1. Demand Side Analysis
• 14.2. Supply Side Analysis

15 VALUE CHAIN ANALYSIS

16 COMPETITIVE SCENARIO

• 16.1. Competitive Landscape
  • 16.1.1. Porters Fiver Forces Analysis

17 COMPANY PROFILED

• 17.1. Bristol-Myers Squibb Company
• 17.2. Novartis AG
• 17.3. Pfizer Inc.
• 17.4. Genentech, Inc
• 17.5. GSK plc.
• 17.6. Bayer AG
• 17.7. Eisai Co., Ltd
• 17.8. Exelixis, Inc.
• 17.9. Merck KGaA
• 17.10. NiKang Therapeutics, Inc.

18 DISCLAIMER